ABBOTT LABORATORIES
Fiscal years labelled by the calendar year in which they end. Bars in $ billions; per-share figures as reported.
CAPITALIZATION 12/31/25
| ($ millions) | Amount | % |
|---|---|---|
| Total debt | 12,929 | 19.9 |
| Stockholders' equity | 52,130 | 80.1 |
| Total capitalization | 65,059 | 100.0 |
1,741,812,429 shares outstanding at 31 March 2026 (cover page of the 10-Q filed 29 April 2026).
LONG-TERM DEBT 12/31/25
| ($ millions) | Amount |
|---|---|
| Long-term debt, incl. current maturities | 12,929 |
| Long-term debt, noncurrent | 9,896 |
| Current maturities | 3,033 |
CAPITAL STOCK 12/31/25
| Common shares authorized | 2,400,000,000 |
| Common shares issued | 1,996,795,525 |
| Treasury shares | 260,196,074 |
| Preferred stock ($ millions) | 0 |
| Outstanding at 3/31/26 | 1,741,812,429 |
DIVIDENDS DECLARED/PAID
| Fiscal year | Per share $ | Payout % |
|---|---|---|
| 2025 | 2.40 | 64.5 |
| 2024 | 2.24 | 29.3 |
| 2023 | 2.08 | 63.8 |
| 2022 | 1.92 | 49.1 |
| 2021 | – | – |
HISTORY AND BUSINESS
HISTORY: Incorporated in Illinois.
BUSINESS: Classified by the SEC under Standard Industrial Classification 2834, Pharmaceutical Preparations. Large accelerated filer. Principal executive office: 100 Abbott Park Road, Abbott Park, IL 60064-3500. Fiscal year ends December 31. For a description of the business, see Item 1 of the latest 10-K.
CONSOLIDATED INCOME ACCOUNT, YEARS ENDED
| ($ millions) | 12/31/25 | 12/31/24 | 12/31/23 |
|---|---|---|---|
| Revenues | 44,328 | 41,950 | 40,109 |
| Cost of revenues | 19,319 | 18,706 | 17,975 |
| Research and development | 2,942 | 2,844 | 2,741 |
| Selling, general and administrative | 12,332 | 11,697 | 10,949 |
| Depreciation and amortization | 1,434 | 1,340 | 1,277 |
| Operating income | 8,053 | 6,825 | 6,478 |
| Interest expense | 493 | 559 | 637 |
| Income before income taxes | 8,466 | 7,013 | 6,664 |
| Income taxes | 1,942 | (6,389) | 941 |
| Net income | 6,524 | 13,402 | 5,723 |
| Earned per share, diluted ($) | 3.72 | 7.64 | 3.26 |
| Dividends per share ($) | 2.40 | 2.24 | 2.08 |
CONSOLIDATED BALANCE SHEET
| ($ millions) | 12/31/25 | 12/31/24 |
|---|---|---|
| Cash and equivalents | 8,522 | 7,616 |
| Receivables, net | 7,929 | 6,925 |
| Inventories | 6,488 | 6,194 |
| Total current assets | 25,996 | 23,656 |
| Property, plant and equipment, net | 11,816 | 10,658 |
| Goodwill | 24,035 | 23,108 |
| Total assets | 86,713 | 81,414 |
| Total current liabilities | 16,496 | 14,157 |
| Long-term debt | 9,896 | 12,625 |
| Stockholders' equity | 52,130 | 47,664 |
| Total liabilities and equity | 86,713 | 81,414 |
TEN-YEAR STATISTICS: FISCAL YEARS ($ millions except per share)
| Fiscal year ended | Revenues | Oper. income | Net income | Net margin % | EPS diluted $ | Div. per share $ | Oper. cash flow | Capital expend. | Free cash flow | Total assets | Total liabilities | Total debt | Stockholders' equity | ROE % | Debt / equity |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 12/31/25 | 44,328 | 8,053 | 6,524 | 14.7 | 3.72 | 2.40 | 9,566 | 2,171 | 7,395 | 86,713 | 33,942d | 12,929 | 52,130 | 12.5 | 0.25 |
| 12/31/24 | 41,950 | 6,825 | 13,402 | 31.9 | 7.64 | 2.24 | 8,558 | 2,207 | 6,351 | 81,414 | 33,513d | 14,125 | 47,664 | 28.1 | 0.30 |
| 12/31/23 | 40,109 | 6,478 | 5,723 | 14.3 | 3.26 | 2.08 | 7,261 | 2,202 | 5,059 | 73,214 | 34,387d | 14,679 | 38,603 | 14.8 | 0.38 |
| 12/31/22 | 43,653 | 8,362 | 6,933 | 15.9 | 3.91 | 1.92 | 9,581 | 1,777 | 7,804 | 74,438 | 37,533d | 16,773 | 36,686 | 18.9 | 0.46 |
| 12/31/21 | 43,075 | 8,425 | 7,071 | 16.4 | 3.94 | – | 10,533 | 1,885 | 8,648 | 75,196 | 39,172d | 18,050 | 35,802 | 19.8 | 0.50 |
| 12/31/20 | 34,608 | 5,357 | 4,495 | 13.0 | 2.50 | – | 7,901 | 2,177 | 5,724 | 72,548 | 39,545d | 18,747 | 32,784 | 13.7 | 0.57 |
| 12/31/19 | 31,904 | 4,532 | 3,687 | 11.6 | 2.06 | – | 6,136 | 1,638 | 4,498 | 67,887 | 36,586d | 18,139 | 31,088 | 11.9 | 0.58 |
| 12/31/18 | 30,578 | 3,650 | 2,368 | 7.7 | 1.33 | – | 6,300 | 1,394 | 4,906 | 67,173 | 36,451d | 19,566 | 30,524 | 7.8 | 0.64 |
| 12/31/17 | 27,390 | 1,564 | 477 | 1.7 | 0.27 | – | 5,570 | 1,135 | 4,435 | 76,250 | 45,152d | 27,924 | 30,897 | 1.5 | 0.90 |
| 12/31/16 | 20,853 | 3,026 | 1,400 | 6.7 | 0.94 | – | 3,203 | 1,121 | 2,082 | 52,666 | 31,949d | 22,006 | 20,538 | 6.8 | 1.07 |
Net margin = net income ÷ revenues; ROE = net income ÷ year-end stockholders’ equity; total debt = long-term debt including current maturities plus short-term borrowings/commercial paper, as tagged in XBRL; free cash flow = operating cash flow − purchases of property, plant and equipment; d = derived as total assets − total equity where the filing does not tag total liabilities; – = not reported in XBRL for that year.
REGISTRANT:
ABBOTT LABORATORIES
CIK 1800 · EIN 36-0698440
PRINCIPAL OFFICE:
100 Abbott Park Road, Abbott Park, IL 60064-3500
Tel.: 2246676100
INCORPORATED:
Illinois
INDUSTRY (SEC SIC CODE):
2834 · Pharmaceutical Preparations
FILER STATUS:
Large accelerated filer
LATEST ANNUAL REPORT:
10-K for period ended 12/31/25, filed 20 February 2026
Sources: SEC XBRL company facts (all financial figures) · SEC submissions (registrant, address, SIC, filings) · annual reports: 10-K FY2025 (filed 2/20/26) · 10-K FY2024 (filed 2/21/25) · 10-K FY2023 (filed 2/16/24) · 10-K FY2022 (filed 2/17/23) · 10-K FY2021 (filed 2/18/22) · 10-K FY2020 (filed 2/19/21) · 10-K FY2019 (filed 2/21/20) · 10-K FY2018 (filed 2/22/19). Values are the latest figures filed for each fiscal year (restated where a later 10-K restated them). Ratios and free cash flow are Pathos calculations from those figures. Retrieved 31 October 2026.
Data from SEC filings. © 2026 Pathos Investments · pathosinvestments.com · For educational purposes only. Not investment advice.